ABSTRACT
Mass vaccination with the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine (BNT162b2) in Korea has resulted in many reported adverse effects. These side effects are the object of much scrutiny in the medical community. We report the case of a 29-year-old male who was diagnosed with myopericarditis after his second dose of Pfizer-BioNTech COVID-19 vaccine. This patient is the second recognized case of Pfizer-BioNTech COVID-19 vaccine induced myopericarditis in Korea and the first to have recovered from it. He originally presented with chest discomfort and exertional chest pain. Lab tests revealed elevated cardiac marker levels and echocardiographic findings displayed minimal pericardial effusion, prompting diagnosis as myopericarditis. We decided on two weeks of outpatient treatment with non-steroidal anti-inflammatory drugs (NSAIDs) due to the patient's mild symptoms and his occupation in the military. When this proved insufficient, we shifted to combination therapy with low dose corticosteroids and NSAIDs. After two weeks of treatment, the patient's symptoms and pericardial effusion had improved, and he was recovered completely 37 days after the onset.
ABSTRACT
Mass vaccination with the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine (BNT162b2) in Korea has resulted in many reported adverse effects. These side effects are the object of much scrutiny in the medical community. We report the case of a 29-year-old male who was diagnosed with myopericarditis after his second dose of Pfizer-BioNTech COVID-19 vaccine. This patient is the second recognized case of Pfizer-BioNTech COVID-19 vaccine induced myopericarditis in Korea and the first to have recovered from it. He originally presented with chest discomfort and exertional chest pain. Lab tests revealed elevated cardiac marker levels and echocardiographic findings displayed minimal pericardial effusion, prompting diagnosis as myopericarditis. We decided on two weeks of outpatient treatment with non-steroidal anti-inflammatory drugs (NSAIDs) due to the patient's mild symptoms and his occupation in the military. When this proved insufficient, we shifted to combination therapy with low dose corticosteroids and NSAIDs. After two weeks of treatment, the patient's symptoms and pericardial effusion had improved, and he was recovered completely 37 days after the onset.
ABSTRACT
It is generally accepted that vigorous exercise may trigger cardiovascular accidents if underlying cardiovascular disease is present. Coronary artery disease is the most frequent cause of sudden cardiac arrest, especially in older individuals (> or = 35 years of age). We describe two patients who presented with cardiac arrest followed by loss of consciousness. Both had been participating in a marathon race. After acute myocardial infarction was diagnosed by electrocardiography and laboratory findings, urgent percutaneous coronary intervention was performed on both patients.
Subject(s)
Adult , Humans , Cardiovascular Diseases , Racial Groups , Coronary Artery Disease , Death, Sudden, Cardiac , Electrocardiography , Heart Arrest , Myocardial Infarction , Percutaneous Coronary Intervention , UnconsciousnessABSTRACT
Coronary artery involvement leading to acute coronary syndrome is a rare complication of essential thrombocythemia. A 43-year-old woman with essential thrombocythemia complained of severe acute chest pain. She had undergone percutaneous coronary intervention (PCI) with a drug-eluting stent (DES), due to unstable angina, 3 and 2 years earlier. Emergency coronary angiography revealed total occlusion of the DES with thrombus. Twenty minutes after successful primary PCI with a DES, an acute stent thrombosis developed. She was subsequently treated with coronary artery bypass graft surgery.
Subject(s)
Adult , Female , Humans , Acute Coronary Syndrome , Angina, Unstable , Chest Pain , Coronary Angiography , Coronary Artery Bypass , Coronary Vessels , Drug-Eluting Stents , Emergencies , Percutaneous Coronary Intervention , Stents , Thrombocythemia, Essential , Thrombosis , TransplantsABSTRACT
Myocardial involvement with clinical symptoms is a rare manifestation of systemic lupus erythematosus (SLE), despite the relatively high prevalence of myocarditis at autopsies of SLE patients. In this review, we report the case of a 19-year-old male SLE patient who initially presented with myopericarditis and was successfully treated with high dose of glucocorticoids.
